HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics

Journal of Drug Targeting

Volumn 12, Issue 8, 2004, Pages 503-515

  Vicent, María J ^a   Manzanaro, Sonia ^b   De la Fuente, Jesús A ^b   Duncan, Ruth ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Instituto Biomar SA   (Spain)

Author keywords

1,5 diazaanthraquinone; Conjugates; Polymer therapeutics; Solubility enhancement

Indexed keywords

1 DIMETHYLAMINO 4 (3 METHOXY 4 PHENOL) 1 AZA 1,3 BUTADIENE; 3 [2 METHOXY 4 (8 METHYL 5,10 DIOXO 5,10 DIHYDROPYRIDO[2,3 G]GUINOLIN 4 YL)PHENOXY]PROPYL AMMONIUM; 6 BROMO 3 METHYL 5,8 QUINOLINEQUINONE; [3 [2 METHOXY 4 (8 METHYL 5,10 DIOXO 5,10 DIHYDROPYRIDO[2,3 G]GUINOLIN 4 YL)PHENOXY]PROPYL]CARBAMIC ACID TERT BUTYL ESTER; [3 [4 [3 (DIMETHYLHYDRAZONO)PROPENYL] 2 METHOXYPHENOXY]PROPYL]CARBAMIC ACID TERT BUTYL ESTER; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG CARRIER; HEMOGLOBIN; LYSOSOME ENZYME; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; POLYMER; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOCYTOSIS; FOURIER TRANSFORM MASS SPECTROMETRY; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INTERNALIZATION; LIVER LYSOSOME; MELANOMA B16; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAMAN SPECTROMETRY; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; MELANOMA, EXPERIMENTAL; METHACRYLATES; MICE; POLYMERS; RATS;

EID: 11444249827     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860400011901     Document Type: Article

References (68)

1. Abe, N., Enoki, N., Nakakita, Y., Uchida, H., Nakamura, T. and Munekata, M. (1993) "Novel antitumor antibiotics, saptomycins. 2. Isolation, physicochemical properties and structure elucidation" , J. Antibiot. 46, 1536-1549.
2. Anon (2000) Expert Opin. Ther. Pat. 10, 977-980.
3. Avendaño, C., Pérez, J.M., Del Mar Blanco, M., Menéndez, J.C., Garcia-Gravalos, D., De la Fuente, J.A. and Martín, M.J. (2002) "Antitumour 1,5-diazanthraquinones" , US Patent Application 0099066.
4. Borchmann, P. and Reiser, M.I. (2003) "Plixantrone novuspharma", Drugs 6, 486-490.
5. Caiolfa, V.R., Zamai, M., Fiorino, A., Frigerio, E., Pellizzoni, C., d'Argy, R., Ghiglieri, A., Castelli, M.G., Farao, M., Pesenti, E., Gigli, M., Angelucci, F. and Suarato, A. (2000) "Polymer-bound camptothecin: initial biodistribution and antitumour activity studies", J. Control. Release 65, 105-119.
6. Configliacchi, E., Razzano, G., Rizzo, V. and Vigevani, A. (1996) "HPLC methods for the determination of bound and free doxorubicin, and of bound and free galactosamine, in methacrylamide polymer-drug conjugates", J. Pharm. Biomed. Anal. 15, 123-129.
7. Corbett, T.H., Valeriote, F.A., Demchik, L., Polin, L., Panchapor, C., Pugh, S., White, K., Knight, J., Jones, J., Jones, L., LoRusso, R, Foster, B., Wiegand, R.A., Lisow, L., Golakoti, T., Heltzel, C.E., Ogino, J., Patterson, G.M. and Moore, R.E. (1996) "Preclinical anticancer activity of cryptophycin-8", J. Exp. Ther. Oncol. 1 95-108.
8. DeIsabella, R, Palumbo, M., Sissi, C., Carenini, N., Capranico, G., Menta, E., Oliva, A., Spinelli, S., Krapcho, A.R, Giuliani, F.C. and Zunino, F. (1997) "Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones", Biochem. Pharmacol. 53, 161-169.
9. De la Fuente, J.A., Martín, M.J., Del Mar Blanco, M., Pascual-Alfonso, E., Avendaño, C. and Menéndez, J.C. (2001) "A C-ring regioisomer of the marine alkaloid meridine exhibits selective in vitro cytotoxicity for solid tumours", Bioorg. Med. Chem. 9, 1807-1814.
10. Duncan, R. (1992) "Drug-polymer conjugates: potential for improved chemotherapy", Anti-cancer Drugs 3, 175-210.
11. Duncan, R. (2003a) "The dawning era of polymer therapeutics", Nat. Rev. Drug Discov. 2, 347-360.
12. Duncan, R. (2003b) "Polymer-Drug conjugates", In: Budman, D., Calvert, H. and Rowinsky, E., eds, Handbook of Anticancer Drug Development (Lippincott Williams & Wilkins, Baltimore), pp 239-260.
13. Duncan, R., Cable, H.C., Lloyd, J.B., Rejmanova, P. and Kopecek, J. (1984) "Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side chains in poly N-(2-hydroxypropyl)methacrylamide copolymers to promote efficient degradation by lysosomal enzymes", Makromol. Chem. 184, 1997-2008.
14. Duncan, R., Bhakoo, M., Riley, M-L. and Tuboku-Metzger, A. (1991) "Soluble polymeric drug carriers: Haematocompatibility" , In: Gomez-Fernandez, Chapman and Packer, eds, Progress in Membrane Biotechnology (Birkhauser Verlag, Basel), pp 253-265.
15. Gasteiger, J. and Marsili, M. (1980) "Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges", Tetrahedron 36, 3219-3228.
16. Gianasi, E., Wasil, M., Evagorou, E.G., Keddle, A., Wilson, G. and Duncan, R. (1999) "HPMA copolymer platinates as novel antitumor agents: in-vitro properties, pharmacokinetics and antitumor activity in vivo", Eur. J. Cancer 35, 994-1002.
17. Gianasi, E., Buckeley, R.G., Latigo, J., Wasil, M. and Duncan, R. (2002) "HPMA copolymer platinates containing dicarboxilato ligands. Preparation, characterisation and in vitro and in vivo evaluation", J. Drug Target. 10, 549-556.
18. Halgren, T.A. (1996a) "Merck molecular force field. 1. Basis, form, scope, parameterization, and performance of MMFF94", J. Comput. Chem. 17, 490-519.
19. Halgren, T.A. (1996b) "Merck molecular force field. 2. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions", J. Comput. Chem. 17, 520-552.
20. Halgren, T.A. (1996c) "Merck molecular force field. 3. Molecular geometries and vibrational frequencies for MMFF94", J. Comput. Chem. 17, 553-586.
21. Halgren, T.A. and Nachbar, R.B. (1996d) "Merck molecular force field. 4. Conformational energies and geometries for MMFF94", J. Comput. Chem. 17, 587-615.
22. Halgren, T.A. (1996e) "Merck molecular force field. 5. Extension of MMFF94 using experimental data, additional computational data, and empirical rules", J. Comput. Chem. 17, 616-641.
23. Hansen, M.R. and Hurley, L.H. (1996) "Pluramycins. old drugs having modern friends in structural biology", Acc. Chem. Res. 29, 249-258.
24. Hertzberg, R.P. and Dervan, P.B. (1984) "Cleavage of DNA with methidiumpropyl-edta-iron (ii) - reaction conditions and product analyses", Biochemistry 23, 3934-3945.
25. Horiguchi, Y., Toeda, K., Tomoda, K. and sano, T. (2000) "Regioselective synthesis of 1,5-diazaanthraquinones via Diels-Alder reaction of 4-hydroxy-quinolinequinone with 1-aza-1,3-butadiene", Heterocycles 53, 315.
26. Konishi, M., Ohkuma, H., Tsuno, T., Oki, T., Van Duyne, G.D. and Clardy, J. (1990) "Crystal and molecular-structure of dynemicin-a - a novel 1,5-diyn-3-ene antitumor antibiotic", J. Am. Chem. Soc. 112, 3715-3716.
27. Kopecek, J., Rejmavova, P., Strohalm, J., Ulbrich, K., Rihova, B., Chytry, V., Duncan, R., Lloyd, J.B. British patent Appl., 8500209 (4.1.85), 1985.
28. Krapcho, A.P., Maresch, M.J., Hacker, M.P., Hazelhurst, L., Menta, E., Oliva, A., Spinelli, S., Beggiolin, G., Giuliani, F.C., Pezzoni, G. and Tignella, S. (1995) "Anthracene-9,10-diones and aza bioisosteres as antitumor agents", Curr. Med. Chem. 2, 803-824.
29. Lévesque, S. and Brassard, P. (1994) "The regiochemistry of 6-chloro-5,8-quinolinequinones and 7-chloro-5,8-quinolinequinones", Heterocycles 38, 2205-2218.
30. Li, C., Yu, D-F., Newman, R.A., Cabral, F., Stephens, C., Hunter, N.R., Milas, L. and Wallace, S. (1998) "Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate", Cancer Res. 58, 2404-2409.
31. López-Alvarado, P., Avendaño, C. and Menéndez, J.C. (2002) "Efficient, multigram-scale synthesis of three 2,5-dihalobenzoquinones", Synthetic Commun. 32, 3233-3239.
32. Lown, J.W. (1993a) "Discovery and development of anthracycline antitumor antibiotics", Chem. Soc. Rev. 22, 165-176.
33. Lown, J.W. (1993b) "Anthracycline and anthraquinone anticancer agents - current status and recent developments", Pharmacol. Ther. 60, 185-214.
34. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. and Hori, K. (2000) "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review", J. Control. Release 65, 271-284.
35. Menon, K., Alvarez, E., Forler, P., Phares, V., Amsrud, T., Shih, C., Al-Awar, R. and Teicher, B.A. (2000) "Antitumor activity of cryptophycins: effect of infusion time and combination studies", Cancer Chemth. Pharm. 46, 142-149.
36. Menozzi, M., Valentín, L., Vanini, E. and Arcamone, F. (1984) "Self-association of doxorubicin and related-compounds in aqueous-solution", J. Pharm. Sci. 73, 766-770.
37. Miyagawa, N., Sasaki, D., Matsuoka, M., Imanishi, M., Ando, T. and Sugiura, Y. (2003) "DNA cleavage characteristics of non-protein enediyne antibiotic N1999A2", Biochem. Biophys. Res. Commun. 306, 87-92.
38. MOE (The Molecular Operating Environment); 2002.03 ed., Chemical Computing Group Inc.: 1010 Sherbrooke Street West, Suite 910, Montreal, Canada H3A 2R7. http://www.chemcomp.com
39. Monneret, C. (2001) "Recent developments in the field of antitumour anthracyclines", Eur J. Med. Chem. 36, 483-493.
40. Muggia, F.M. (1999) "Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention" , Clin. Cancer Res. 5, 7-8.
41. Nebois, P., Carneiro, do Nascimento, S., Boitard, M., Bartoli, M.H. and Fillion, H. (1994) "Synthesis and in vitro cytotoxic activity of aza-and diazaanthraquinone derivatives", Pharmazie 49, 819-821.
42. Nicolaou, K.C., Dai, W.-M., Hong, Y.P., Tsay, S.-C., Baldridge, K.K. and Siegel, J.S. (1993) "Molecular design, chemical synthesis, kinetic-studies, calculations, and biological studies of novel enediynes equipped with triggering, detection, and deactivating devices - model dynemicin - a epoxide and cis-diol system", J. Am. Chem Soc. 115, 7944-7953.
43. Pan, S.S., Pedersen, L. and Bachur, N.R. (1981) "Comparative flavoprotein catalysis of anthracycline antibiotic - reductive cleavage and oxygen-consumption", Mol. Pharmacol. 19, 184-186.
44. Pérez, J.M., López-alvarado, P., Avendaño, C. and Menéndez, J.C. (2000) "Concise preparation of 1,8-diazaandiracene-2,7,9,10-tetraones. Two alternative syntheses of the natural antifolate diazaquinomycin A", Tetrahedron 56, 1561-1567.
45. Rathelot, P., Remusat, V. and Vanelle, P. (2002) "Synthesis of 3-alkenyl-1-azaanthraquinones via Diels-Alder and electron transfer reactions", Molecules 7, 917-921.
46. Rejmanova, P., Labsky, J. and Kopecek, J. (1977) "Aminolyses of monomeric and polymeric p-nitrophenyl esters of methacryloylated amino acids", Makromol. Chem. 178, 2159-2168.
47. Rowinsky, E.K., Rizzo, J., Ochoa, L., Takimoto, C.H., Forouzesh, B., Schwartz, G., Hammond, L.A., Patnaik, A., Kwiatek, J., Goetz, A., Denis, L., McGuire, J. and Tolcher, A.W. (2003) "A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies" , J. Clin. Oncol. 21, 148-157.
48. Searle, F., Gac-Breton, S., Keane, R., Dimitrijevic, S., Brocchini, S., Sausville, E.A. and Duncan, R. (2001) "N-(2-hydroxypropyl)-methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates, synthesis, characterisation and preliminary in vitro and in vivo studies", Bioconjug. Chem. 12, 711-718.
49. Seymour, L.W., Ulbrich, K., Wedge, S.R., Hume, I.C., Strohalm, J. and Duncan, R. (1991) "N-(2-Hydroxypropyl Methacrylamide copolymers targeted to the hepatocyte galactose-receptor - pharmacokinetics in Dba2 mice", Br. J. Cancer 63, 859-866.
50. Seymour, L.W., Ferry, D.R., Anderson, D., Hessleword, S., Julyan, P.J., Poyner, R., Doran, J., Young, A.M., Burtles, S. and Kerr, D.J. (2002) "Hepatic drug targeting: Phase I evaluation of polymer bound doxorubicin", J. Clin. Oncol. 20, 1668-1676.
51. Sgouras, D. and Duncan, R. (1990) "Methods for the evaluation of biocompatibility of soluble synthetic polymers which have potential for biomedical use. 1 Use of a tetrazolium-based colorimetric assay (MTT) as a preliminary screen for the evaluation of in vitro cytotoxicity", J. Mater. Sci.: Mater. Med. 1, 61-68.
52. Singer, J.W., Baker, B., de Vries, P., Kumar, Shaffer, S. and Vawter, E. (2003) "Poly-(L)-Glutamic acid-paclitaxel (CT-2103)[XYOTAX™], a biodegradable polymeric drug conjugate" , Adv. Exp. Med. Biol. 519, 81-99.
53. Skrobisz, A. and Konopa, J. (2002) "Interstrand crosslinking of DNA in tumor cells by anthracenediones, and the relevance of this ability to cytotoxic and antitumor properties of these compounds", Int. J. Cancer Suppl. 13, 440-441.
54. Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J. and Klenk, D.C. (1985) "Measurement of protein using bicinchoninic acid", Anal. Biochem. 150, 76-85.
55. Sperry, S., Valeriote, F.A., Corbett, T.H. and Crews, P. (1998) "Dihydrotubastrines: phenethylguanidine analogues from the indo-pacific marine sponge petrosia cf. contignata", J. Nat. Prod. 61, 241-247.
56. Subr, V., Kopecek, J. and Duncan, R. (1986) "Degradation of oligopeptide sequences connecting poly[N-(2-hydroxypropyl)methacrylamide] chains by lysosomal cysteine proteinases", J. Bioact. Compat. Polym. 1, 133-146.
57. Subr, V., Strohalm, J., Ulbrich, K. and Duncan, R. (1992) "Polymers containing enzymatically degradable bonds, XII. Release of daunomycin and adriamicyn from poly[N-(2-hydroxypropyl)methacrylamide] copolymers", J. Control. Release 18, 123-132.
58. Subr, V., Strohalm, J., Hirano, T., Ito, Y. and Ulbrich, K. (1997) "Poly-[N-(2-hydroxypropyl) methacrylamide] conjugates of methotrexate - Synthesis and in vitro drug release", J. Control. Release 49, 123-132.
59. Sun, D., Hansen, M. and Hurley, L. (1995) "Molecular-basis for the DNA-sequence specificity of the pluramycins - a novel mechanism involving groove interactions transmitted through the helix via intercalation to achieve sequence selectivity at the covalent bonding step", J. Am. Chem. Soc. 117, 2430-2440.
60. Tapia, R.A., Quintanar, C. and Valderrama, J.A. (1996) "Approach to the synthesis of 1,5-diazaanthraquinones by Diels-Alder reactions of quinoline-5,8-diones", Heterocycles 43, 447-461.
61. Terwogt, J.M.M., Bokkel Huinink, W.W., Schellens, J.H.M., Schot, M., Mandjes, I.A.M., Zurlo, M.G., Rocchetti, M., Rosing, H., Koopman, F.J. and Beijnen, J.H. (2001) "Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel", Anticancer drugs 12 315-323.
62. Trimurtulu, G., Ohtani, I., Patterson, G.M.L., Moore, R.E., Corbett, T.H., Valeriote, F.A. and Demchik, L. (1994) "Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green-alga nostoc sp strain Gsv-224", J. Am. Chem. Soc. 116, 4729-4737.
63. Trouet, A. (1974) "Isolation of modified liver lysosomes", In: Fleischer, S. and Packer, L., eds, Methods in Enzymology (Academic Press), Vol. XXXI, pp 323-329.
64. Ulbrich, K., Konak, C., Tuzar, Z. and Kopecek, J. (1987) "Solution properties of drug carriers based on poly[N-(2-hydroxypropyl)-methacrylamide] containing biodegradable bonds", Makromol. Chem. 188, 1261-1272.
65. Vasey, P.A., Kaye, S.B., Morrison, R., Twelves, C., Wilson, P., Duncan, R., Thomson, A.H., Murray, L.S., Hilditch, T.E., Murray, T., Burtles, S., Fraier, D., Frigerio, E. and Cassidy, J. (1999) "Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents: drug-polymer conjugates", Clin. Cancer Res. 5, 83-94.
66. Vicent, M.J., Paul, A., Griffiths, P.C. and Duncan, R. (2004) "Using small angle neutron scattering (SANS) to evaluate the conformation of PK1 and PK2: a potential explanation for their clinical behaviour", In Proc. Int'l. Symp. Polym. Ther., 50.
67. Waldner, A. (1988) "[4 + 2] Cyclo-additions of alpha,beta-unsaturated hydrazones to pyridine-2,3-dicarboximides via 1-(dimethylamino)-1, 4-dihydropyridine derivatives", Helv. Chim. Acta 71, 486-492.
68. Young, T.K., Hopewell, J.W., Simmonds, R.H., Seymour, L.W., Duncan, R., Bellini, O., Grandi, M., Spreafico, F., Strohalm, J. and Ulbrich, K. (1991) "Reduced cardiotoxicity of doxorubicin given in the form of n-(2-hydroxypropyl)mediacrylamide conjugates - an experimental-study in the rat", Cancer Chemother Pharmacol. 29 105-111.